Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Add To Watchlist

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Salzman Group may receive additional USD $20 million-COVID!

View:

Post by CBDKings on May 29, 2020 12:04pm

Salzman Group may receive additional USD $20 million-COVID!

Salzman Group is also developing R-107 for chlorine inhalation lung injury (“CILI”). This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600016C (the "BARDA Contract"). Salzman Group will make an application for an additional BARDA contract to develop R-107 for treatment of COVID-19 associated lung disease. The potential total funding under the BARDA Contract for development of R-107 for CILI is USD $84.9 million. If Salzman Group’s application for a new BARDA contract for development of R-107 for COVID-19 associated lung disease is successful, Salzman Group may receive an additional USD $20 million under this new BARDA contract.

170